Combining Biologic Therapies for Psoriasis with other Systemic Agents: A Review of Safety Data

Bresnihan B. , Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003; 29(1): 185–202.

Remicade (infliximab) package insert. Centocor, Inc. 2002.

Keane J. , Gershon S. , Wise R.P. , Maribile-Levens E. , Kasznica J. , Schwieterman W.D. , Siegel J.N. , Braun M.M. Tuburculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098–104.

Lipsky P.E. , van der Heijde D.M. , St Clair E.W. , Purst D.E. , Breedveld F.C. , Kalden J.R. , Smolen J.S. , Weisman M. , Emery P. , Feltmann M. , Harriman G.R. , Maini R.N. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343(22): 1594–602.

Maini R. , St Clair E.W. , Breedveld F. . Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–1939.

Lipsky P. , van der Heijde D. , St Clair W. . 102-week clinical & radiological results from the Attract trial: a 2-year, randomized, controlled, phase 3 trial of infliximab (Remicade) in patients with active RA despite MTX. Arthritis Rheum 2000; 43: S269.

Maini R.N. , Breedveld F.C. , Kalden J.R. . Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–1563.

Shergy W.J. , Esern R.A. , Cooley D.A. , Harshbarger J.L. . PROMP Study Group. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002; 29(4): 667–77.

Ferraccioli G.F. , Assaloni R. , Di Poi E. , Gremese E. , De Marchi G. , Fabris M. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology 2002; 41: 1109–1112.

Temekonidis T.I. , Georgiadis A.N. , Alemanos Y. , Bougais D.V. , Voulgari P.V. , Drosos A.A. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 2002; 61(9): 822–5.

Weinblatt M.E. , Kremer J.M. , Bankhurst A.D. . Atrial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–259.

Enbrel (etanercept) package insert. Immunex Corporation, 2001.

Data in file. Amgen Pharmaceuticals.

Kremer J.M. , Weinblatt M.E. , Bankhurst A.D. , Bulpitt K.J. , Fleischmann R.M. , Jackson C.G. , Atkins K.M. , Feng A. , Burge D.J. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003; 48(6): 1493–9.

Phillips K. , Husni M.E. , Karlson E.W. , Coblyn J.S. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002; 47(1): 17–21.

Gottlieb A. The New World of Psoriasis Treatment: Could This Be the Answer for You? http://www.healthtalkinteractive.com/psoriasis/100902/16.html. Posted 10/9/02.

Feldman S. , Hu J. Psoriasis and Quality of Life. In Medscape Online http://www.medscape.com/viewarticle/453360. Viewed 7/30/03.

http://www.hopkins-arthritis.som.jhmi.edu/edu/eular2003/ra-treatments-tcell.html. Viewed 8/29/03.